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Summary 
PHOSPHO1, a new member of the haloacid dehalogenase superfamily, has recently 
been implicated in the mineralization process in both osteoblasts and chondrocytes. In 
this study we describe the identification of a novel, alternatively spliced PHOSPHO1 
transcript (PHOSPHO1-3a). This transcript contains the 3 exons of the previously 
published variant, however exon 3 contains a retained, 127bp section of intron 2. This 
forms an in-frame start site, producing an open reading frame of 879bp and predicting 
a protein of 292 amino acids. The novel 40 amino acid N-terminal region of 
PHOSPHO1-3a contains a relatively strong secretory signal, however all three 
domains of the HAD superfamily are retained in exon 3. The expression of this splice 
variant was confirmed in both human and mouse osteoblast-like cells and also in the 
chondrogenic ATDC5 cell line. The data within this study indicates a possible 
function relating to chondrocyte differentiation/mineralization as with the previously 
published variant. 
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Introduction 
PHOSPHO1 is a phosphatase enzyme belonging to the HAD superfamily of 
hydrolases, which has been implicated in the generation of phosphate (Pi) for skeletal 
mineralization [1]. Initially Phospho1 gene studies were done in the chicken (Gallus 
gallus), however since then EST sequence database entries have been identified 
corresponding to human and murine Phospho1 which have been subsequently 
amplified and cloned [2]. These transcripts have a 94% identity to each other and are 
62% identical to chick Phospho1. The human and murine Phospho1 genes lie within 
approximately 7.4Kb regions on HSA17q21.32 and distal MMU11 respectively, are 
flanked by the ACLY and GH1 loci, and exhibit conservation of synteny with part of 
GGA27. Using genetic linkage analysis, chick Phospho1 was mapped to the syntenic 
region on GGA27 [2]. This strongly suggests that the Phospho1 loci on HSA17 and 
MMU11 are orthologous to the Phospho1 gene originally identified in the chick.  
Phospho1 has since been identified in a number of species including rat, zebrafish and 
puffer fish through EST analysis [3]. 
PHOSPHO1 has been shown to have a high specific phosphohydrolase activity 
toward phosphoethanolamine (PEA) and phosphocholine (PCho) substrates [4]. PEA 
and PCho are involved in the biosynthesis of phosphatidylethanolamine and 
phosphatidylcholine, respectively, and form the polar headgroups of phospholipids in 
biological membranes. Both PEA and PCho levels are controlled in vivo by the 
expression of CTP-dependent cytidyltransferases, which catalyse the formation of 
CDP-ethanolamine and CDP-choline, respectively [5; 6].  
Phospho1 is expressed at high levels in bone tissue when compared with non-skeletal 
tissues in both chick and murine models [7; 8]. Immunolocalization studies have 
shown that PHOSPHO1 is specifically localized to mineralizing regions of skeletal 
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tissue in both species [9]. In addition to the protein localization studies, Phospho1 
transcript has also been localized in developing embryonic bones of the chick by in 
situ hybridization [1]. In this study the transcript of Phospho1 has been found to be 
expressed at sites destined for mineralization. Interestingly the transcript is present at 
these sites prior to overt signs of mineralization thereby providing support to the 
suggestion that PHOSPHO1 is involved in the initial stages of mineralization. 
 This expression/localization pattern suggests PHOSPHO1 is closely associated with 
the mineralization process and in particular the generation of Pi for hydroxyapatite 
production. This is an essential phase of mineral formation, not only for the 
precipitation with calcium but initially to raise the Pi/PPi ratio to a degree that is 
permissive to mineralization. This is due to PPi acting as a powerful inhibitor of HA 
formation [10; 11]. In addition, reduction of PHOSPHO1 activity through the use of 
newly discovered small molecule inhibitors causes a decrease in the capacity of MVs 
to calcify in vitro. These data indicate that PHOSPHO1 has a role in the 
mineralization process which is likely to be in the production of Pi for calcium 
phosphate precipitation.  
In this study we now describe the discovery of a novel Phospho1 transcript which is 
expressed in human osteoblasts. In addition, we present data to suggest that both 
transcripts exist in murine osteoblasts and chondrocytes, suggesting a role in the  
differentiation/mineralization of these skeletal cells. 
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Materials and Methods 
PCR Amplification of Phospho1 variants 
Total RNA was isolated from SaOS-2 human osteoblast-like cells by 
phenol/chloroform extraction and treated with DNase I (Ambion) according to the 
manufacturer's instructions. The RT-PCR reaction was carried out using the 
SUPERSCRIPT - First Strand synthesis system for RT-PCR with Oligo dT (Roche). 
Primer pairs for β-Actin RNA were used as a control. The reaction mixture contained 
5µg RNA, 500ng Oligo dT, 2µl 10 x RT buffer, 2mM MgCl2 , 10mM DTT, 0.5mM 
DNTP’s, 200ul Superscript enzyme. The reaction was then cycled as follows; 25◦C 
for 10 min, 42◦C for 50 min and 70◦C for 15 min. PCR primers (Exon1F 5’-
CCCCCTTCCCCACTTCTTAC-3’, Exon1-2-3aR 5’-CCGGGAGAGGCTGGTTAG-
3’; amplicon size 230bp and Exon1F2 5’-TACCTCAGCTAGCCCCCTTC-3’, 
Exon1-2-3bR 5’-CGGAGATGAGAATCACCTCG-3’; amplicon size 638bp and 
511bp for Phospho1-3a and the previously published isoform respectively) were 
designed to allow amplification of exons created through alternative splice patterns 
(defined by EST analysis). Each transcript was amplified utilizing a 55°C annealing 
temperature and 200ng cDNA. The PCR products were then electrophoresed on a 2% 
agarose gel and purified using the Qiagen QiaQuick gel extraction kit. The PCR 
products were cloned directly into the pGEM-T-Easy vector. This plasmid is pre-
lineralized and can ligate to the deoxyadenosine (A) at the 3´ ends of PCR products.  
The PCR product and plasmid were ligated in a 3:1 ratio using 100ng of PCR product. 
This mixture was used to transform JM109 competent cells. Liquid cultures and 
plasmid minipreparations of individual clones were subsequently carried out. DNA 
sequencing of plasmids was carried out by the DNA sequencing facility at Dundee 
University.  
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Cell Culture 
The ATDC5 chondrocyte cell line was obtained from the RIKEN cell bank (Ibaraki, 
Japan), and cells cultured at a density of 6000 cells/cm2 in differentiation medium 
(DMEM:F12 (Invitrogen, Paisley, UK), 5% FCS (Invitrogen), 3x10-8M sodium 
selenite, 10µg/ml human transferrin (Sigma, Poole, UK) and 10µg/ml insulin  
(Sigma)).  Cells were differentiated at 37oC in a humidified atmosphere containing 
5% CO2 for up to 15 days.  We and others have previously shown that from 8 days of 
differentiation, ATDC5 cells express the chondrocyte marker gene collagen type II, 
and by day 15, the cells display a terminally differentiating phenotype, with increased 
levels of collagen type X and aggrecan expression, and the formation of nodules [12; 
13]. Some cultures were further differentiated for 28 days to induce mineralization in 
the presence of 10mM β-glycerol phosphate (βGP) and 50 µg/ml ascorbate-2-
phosphate.  
Mouse calvarial cells (wild-type Ob) were isolated from 3-day-old mice 
through sequential collagenase digestion. Calvarial cells were plated at a density of 
20,000/cm2 in alpha-MEM (Gibco, Paisley, UK) containing 10% FBS. MLO-A5 [14] 
cells were obtained from L.F. Bonewald (University of Missouri, Kansas City, MO) 
and cultured in a similar manner but seeded at 10,000/ cm2. 
 
PCR of Genes During ATDC5 Differentiation 
RNA was extracted and reverse transcribed as described above. Primers for 
18s RNA were purchased from Applied Biosystems (Warrington, UK). Other primers 
were designed using the software programme Primer3 (Whitehead Institute for 
Biomedical Research); Phospho1: forward 5′- GACAATGAGCGGGTGTTTTC-3′, 
reverse 5′-GGGGATGGTCTCGTAGACAG-3′; Aggrecan: forward 5′-
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CGAGAATGACACCTGCTAGG-3 reverse 5′-AAGAAGACAGGACCAGGAAGG-
3’, Collagen II (Coll2a): forward 5′-GCCAAGACCTGAAACTCTGC-3 reverse 5′-
GGTTGGGGTAGACGCAAGTC-3’. The PCR reaction contained; 0.2mM dNTP 
mix (Promega), 5µl 10x PCR Buffer (Roche), 5 units Taq polymerase (Roche), 
0.5µM of the forward and reverse primers and 1µl cDNA. This was then cycled at: 
94°C for 5 minutes, thirty cycles of 94°C for 30 seconds 55°C for 30 seconds and 
72°C for 1 minute and finally one step on 72°C for 10 minutes. Each reaction was 
analyzed on 1.5% agarose gels run in the presence of ethidium bromide (250 µg/l). 
 
Western Blotting 
Cell extracts were analyzed for the presence of PHOSPHO1 by immunoblotting. Cell 
preparations were lysed in PBS containing 1.6 mg/ml of Complete® protease inhibitor 
cocktail (Roche, Lewes, UK). Samples corresponding to 50 µg total protein were 
incubated at 70˚C for 10 minutes in LDS sample buffer before loading. Samples were 
run on a 10% Bis-Tris NuPAGE gel and electroblotted to nitrocellulose, which were 
incubated in blocking solution (5% non-fat milk in Tris buffered saline with 0.1% 
Tween 20).  The membranes were then probed with a 1:750 dilution of rabbit-anti-
PHOSPHO1 antisera in blocking solution and washed three times with PBS. Blots 
were then incubated with goat anti rabbit IgG-peroxidase (DAKO) diluted 1:2,000 in 
blocking solution. The immune complexes were then visualized by enhanced 
chemiluminescence 
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Results 
Identification of a novel splice variant of Phospho1 
We have previously reported the high expression of Phospho1 in both mineralizing 
growth plate chondrocytes and osteoblasts from murine sources. During these 
previous studies [8] a doublet band was observed upon amplification of Phospho1 
between exons 2 and 3 and we have previously postulated that this was an alternative 
transcript from the Phospho1 gene. The presence of this doublet was confirmed in 
both primary osteoblasts and MLO-A5 cells in this present study (Figure1A). A 
search of ESTs from the human NCBI database revealed a sequence assigned 
BC029931 that perhaps reinforced this hypothesis. This sequence from the Phospho1 
gene had a section of retained intron from intron 2 (Figure 2). In order to investigate 
the possibility of an alternative splice variant, primers were designed to amplify a 
product containing exon one to three. Primers were designed to simultaneously 
amplify both the variant containing the novel exon – termed exon 3a, and the original 
isoform. The amplification products were cloned and sequenced. As seen in Figure 1B 
both splice variants can be amplified from SaOS-2 osteosarcoma cDNA, each 
identical apart from a 127bp exon found at the 5’ region of exon 3 (Figure 2B). The 
novel transcript can be amplified both independently (Figure 2B lane 2) and along 
with the previously published transcript (Figure 2B lane 3), depending on the position 
of the reverse primer.  This novel variant is termed Phospho1-3a. This novel exon 
causes a frame shift, which in turn causes the initiation site from exon 2 to be lost and 
a novel start site to be created in exon 3a. Consequently, an open reading frame of 879 
nucleotides is formed, which can be translated into a protein of 292 amino acids. All 
three motifs which form the conserved active site from the HAD superfamily are 
conserved between both splice variants as they are all located within exon 3. 
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Expression of Phospho1-3a in differentiating chondrocytes 
The Phospho1 splice variants were amplified using primers which crossed intron 2 
and exon 3a of the Phospho1 gene, in order that both variants would be amplified 
together. As can be seen in figure 3A, the ATDC5 cell line progresses from a 
proliferating phenotype at day 0 to a terminally differentiated phenotype with the 
presence of cartilaginous nodules (as indicated by arrows) at day 15. Both splice 
variants are identified in the differentiating cells with apparent equal intensity, 
however there is an increase in both during the initial stages of differentiation, 
between days 0 and 4 (Figure 3B). The differentiation of the chondrocytes is 
confirmed by the increase in expression of Aggrecan during the differentiation 
process. The presence of Collagen II (Coll2a) transcript verifies the chondrocyte like 
phenotype of the cells. 
 
PHOSPHO1 Protein Levels in Differentiating Cells 
To analyze the effect of differentiating factors on the presence of PHOSPHO1 within 
mineralizing ATDC5 cells, the cells were cultured in the presence of 10 mM βGP and 
50 µg/ml ascorbate-2-phosphate. Two forms of PHOSPHO1 (32 and 29KDa) were 
detected in each cell type corresponding to two splice variants from the Phospho1 
gene, as seen in figure 3C. However, PHOSPHO1 appeared to be constitutively 
expressed and protein levels did not alter during the latter phase of matrix 
mineralization. Mineralization was evident by day 22 (data not shown). 
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Discussion  
In this study, we identified a novel splice variant from the Phospho1 gene, named 
Phospho1-3a. The analysis of this splice variant reveals a protein with an alternative 
N terminal region (Figure 4), termed exon 3a. This exon is formed from a retained 
127bp section of intron 2, leading to the formation of a new in frame ATG initiation 
site giving rise to a novel 334bp ORF.  
This is not uncommon within the haloacid dehalogenase superfamily, in fact H+-K+-
ATPases show a somewhat similar splicing pattern with alternative transcriptional 
initiation and mRNA splicing giving rise to distinct N-terminal variants of the 
HKalpha2 subunit [15]. The splice variant of Phospho1 only differs in the N terminal 
region, thus these variants are perhaps encoding PHOSPHO1 proteins with slightly 
different functions within or outside the cell. Interestingly, analysis of the 3a 
sequences with the program SignalP v3.0 [16] suggests the presence of a relatively 
strong secretory domain hinting that this form is either being secreted or signaled to 
alternative sites within the cell (data not shown). All three domains within the 
Phospho1 gene are conserved within exon 3b (Figure 2a), indicating that these splice 
variants are functioning against a common substrate or substrate structure, as is seen 
in H+-K+-ATPases, where N-terminal alteration causes a difference in 
pharmacological profile but not in substrate specificity.  The splicing of pre-mRNA is 
tightly controlled by spliceosomes following gene transcription but before translation. 
These spliceosomes recognise the boundary found between introns and exons, upon 
detection they catalyze the cutting out of intronic sequence and the joining of exons. 
The recognition of specific splice sites relies on the presence of conserved intronic di-
nucleotides at the 5’ (donor) and 3’ (acceptor) exon-intron boundaries. However 
further sequences around the splice site are required for proper splicing [17]. 
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 PHOSPHO1 has been shown to be involved in the mineralization process 
through the production of Pi for hydroxyapatite crystal formation. Its expression is 
restricted to cells of the skeleton where it has been shown to be highly expressed by 
both mineralizing chondrocytes and osteoblasts [7; 8; 9]. Within the epiphyseal 
growth plate, PHOSPHO1 protein has been located to prehypertrophic chondrocytes 
and absent from both proliferating and hypertrophic regions [8; 9]. This observation 
suggests that PHOSPHO1 has a role in the early stages of matrix mineralization. To 
analyse whether Phospho1-3a is differentially expressed during these stages the 
murine chondrogenic ATDC5 cell line was induced to differentiate from a 
proliferating to a terminally differentiated phenotype. Both Phospho1 transcripts were 
identified during this process at an apparent equal expression; however a modest 
increase in expression levels was noted over time, which is in agreement with Chen et 
al (2005) [18]. This is similar to another haloacid dehalogenase – like enzyme, 
Sarco/endoplasmic reticulum-type calcium transport ATPase 2, where a novel splice 
variant was identified to be involved in monocyte differentiation [19]. This splice 
variant, which is formed in a similar fashion to Phospho1-3a – through an inclusion of 
a small section of intronic sequence at the 3’ region of the transcript, is upregulated 
during differentiation. As with PHOSHO1-3a the novel variant of SERCA2 is 
modulated in a similar fashion as the major isoform. This suggests that the novel 
splice variant from the Phospho1 gene may be involved in chondrogenic 
differentiation from a proliferating to hypertrophic phenotype along with the 
previously published isoform.  
As Phospho1 has been implicated in the mineralization process, ATDC5 cells were 
induced to mineralize through the addition of βGP and ascorbate-2-phosphate for a 
period of 28 days. However, upon analysis of PHOSPHO1 protein levels directly pre 
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and proceeding (detectable) matrix mineralization, the transcripts appear to be 
constitutively expressed, although the larger, novel Phospho1-3a is expressed at a 
higher level than the previously published variant, suggesting a possible synergy 
between the two isoforms. Similarly, the HAD enzyme epoxide hydrolase-2 has three 
published isoforms which differ in their N terminal regions only [20; 21]. All three 
isoforms are closely linked to the ovulation process, however exact functions for these 
variants have yet to be identified.  It is therefore possible that this is also the case with 
variants of Phospho1 and the mineralization process. 
Phospho1 expression has been documented in alternative tissues such as heart and 
bone marrow, although at considerably lower levels [8]. The identification of the 
splice variant Phospho1-3a may suggest alternative functions in tissues other than 
bone. Interestingly, PHOSPHO1 has also been shown to be able to cleave PCho, the 
hydrolysis of which has been studied in hamster heart and has been shown to be 
catalysed by an unidentified enzyme [22]. 
Recently PHOSPHO1 has been directly implicated in phase one of matrix vesicle 
mineralization [8]. This process involves the intra-vesicular formation of 
hydroxyapatite crystal and is critical for normal bone growth and maintenance. The 
identification of a novel splice variant from this gene may serve to provide further 
insights into this process or perhaps provide a means for Pi or PEA/Cho production in 
distinct sites. However, elucidation of the precise function and location of Phospho1-
3a would first need to be established. 
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Figure Legends 
Figure 1 PCR products corresponding to splice variants of human Phospho1. (A) 
Amplification of Phospho1 from exon 2 to exon 3 in wild type murine osteoblasts 
(Ob) and pre-osteocytes (MLO-A5) and (B) amplification from exon 2 to exon 3a 
(lane 2) and exon 3 (lane 3) in human SaOS-2 cells. RNA was extracted from each 
cell type and reverse transcribed before being amplified using gene specific primers as 
described in “Materials and Methods”. 
 
Figure 2 Structure of a novel alternatively spliced exon 3a. (A) Schematic 
representation of exon organization and protein domains in the Phospho1 splice 
variant. Arrows indicate alternative ATG start sites.  Note the presence of exon 3a 
does not affect any of the HAD conserved domains located in Exon 3. (B) Phospho1-
3a retains a 127bp portion of intron 2 (corresponding to nucleotides 44657239–
44657366 of human chromosome 17) as a novel exon, termed exon 3a. *consensus 
sequence for RNA splicing acceptor site # consensus sequence for RNA splicing 
donor site. 
 
Figure 3 The effect of chondrocyte differentiation on Phospho1 expression. (A) 
The chondrogenic ATDC5 cells display phenotypic changes when differentiated in 
the presence of sodium selenite, transferrin and insulin, depicted by the presence of 
cartilaginous nodules (indicated by arrows) at day 15 of culture. (B) Expression of 
Phospho1, Aggrecan and Coll2a in ATDC5 cells during differentiation. 
Differentiation was confirmed by the increase in aggrecan expression. RNA was 
extracted from each cell type and reverse transcribed before being amplified using 
gene specific primers as described in “Materials and Methods”. (C) Immunoblot 
examining PHOSPHO1 expression in protein isolated from ATDC5 cells induced to 
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mineralize. The cells were cultured in the presence of 10mM βGP and 50 µg/ml 
ascorbate-2-phosphate. Mineralization of the monolayer was evident by day 22. 
 
Figure 4 Comparison of amino acid alignment of human regular PHOSPHO1 
and PHOSPHO1-3a. The predicted amino acid sequence of PHOSPHO1-3a is 
aligned with the amino acid sequence of human PHOSPHO1. Note the identical 
sequence outwith the N-terminal region. 
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Figure 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
19 
Figure 2 
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Figure 3 
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Figure 4 
 
 
 
 
 
 
 
 
 
 
 
 
 
